June 9-16, 2016
Last Updated: Jun 10, 2016
- Enhanced Risk-Based Lung Cancer Screening May Prevent More Deaths than Current Approaches
NCI, June 2016 - Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.
Imyanitov Evgeny N, et al. Molecular diagnosis & therapy 2016 6 - Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Zwitter Matjaz, et al. Cancer biology & therapy 2016 6 0 - Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
Chen Bin, et al. Cell biochemistry and biophysics 2015 12 (3) 799-804 - The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Gou Lan-Ying, et al. Oncotarget 2016 5 - Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.
D'Haene Nicky et al. PloS one 2015 10(9) e0138245 - Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali Siraj M et al. The oncologist 2016 May - FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer,
FDA, June 1, 2016 - L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated non-small cell lung cancer.
Bersanelli Melissa, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 5 - The unique characteristics of MET exon 14 mutation in Chinese non-small cell lung cancer patients.
Liu Si-Yang, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 5 - Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.
Xie Jing, et al. Molecular genetics & genomic medicine 2016 5 (3) 262-72 - Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Hu Lei, et al. International journal of environmental research and public health 2016 0 (6) - Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam S S, et al. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 5 - Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Jain Deepali, et al. The Indian journal of medical research 2016 3 (3) 308-14 - TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.
Halvorsen Ann R, et al. Frontiers in genetics 2016 0 85 - EGFR TKIs plus WBRT demonstrated no survival benefit than TKIs alone in NSCLC patients with EGFR mutation and brain metastases.
Jiang Tao, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 5 - High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
Scarpino Stefania, et al. Lung cancer (Amsterdam, Netherlands) 2016 7 95-8 - Genotyping of EGFR Mutations from Bronchial Cytological Specimens in Slovakian Lung Cancer Patients.
Baluchova K, et al. Advances in experimental medicine and biology 2016 5 - Haplotype and diplotype analyses of variation in ERCC5 transcription cis-regulation in normal bronchial epithelial cells.
Zhang Xiaolu, et al. Physiological genomics 2016 5 physiolgenomics.00021.2016 - FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer
FDA, June 1, 2016 - Validity of self-reported family history of cancer: A systematic literature review on selected cancers.
Fiederling Jonas et al. International journal of cancer 2016 May - Associations between genetic variants located in mature microRNAs and risk of lung cancer.
Li Dengrui, et al. Oncotarget 2016 5 - Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.
Tu Huakang, et al. Scientific reports 2016 0 26760 - Effect of ATM-111 (G>A) Polymorphism on Cancer Risk: A Meta-Analysis.
Huang Senlin, et al. Genetic testing and molecular biomarkers 2016 5 - Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Yasuaki, et al. Cancer medicine 2016 5 - Role of ATG10 expression quantitative trait loci in non-small cell lung cancer survival.
Xie Kaipeng, et al. International journal of cancer 2016 5 - A novel pathway-based approach improves lung cancer risk prediction using germline genetic variations.
Qian David C, et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2016 5 - Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Zhang Minghui, et al. Oncotarget 2016 5 - [Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation].
Zhang Quan, et al. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2016 5 (5) 257-62 - Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey.
Sag Sebnem Ozemri, et al. SpringerPlus 2016 0 482
- Human (3796)
- Pathogen (0)
- Human (58)
- Pathogen (0)
.png)
No hay comentarios:
Publicar un comentario